ABSTRACT OBJECTIVES This study sought to hypothesize that elevated B-type natriuretic peptide (BNP) could act as an endogenous neprilysin inhibitor.
Production of BNP by stretched cardiomyocytes promotes natriuresis, diuresis, and vasorelaxation to mitigate cardiac overload (7) .
In addition, BNP also exhibits antifibrotic (8) , antihypertrophic (9) , anti-inflammatory (10), and angiogenic (11) actions, and acutely opposes the reninangiotensin-aldosterone (12) and sympathetic nervous systems. Various strategies have been attempted to potentiate the beneficial effects of NPs in both ADHF and stable chronic HF (CHF) patients (13) . These have included the infusion of either recombinant (e.g., nesiritide [14] or ularitide [15] ) or synthetic NPs (e.g., vasonatrin [16] or CD-NP [17] ) and inhibition of the NPdegrading neprilysin (also known as neutral endopeptidase) in combination either with inhibition of the angiotensin-converting enzyme (18) or angiotensin receptor blockade (ARNi, LCZ696 [19] ). Importantly, although the former strategies aim to simply leverage the biological effect of the NPs, the latter approach (i.e., combined agents) may have broader effects because of the broader biological benefits of neprilysin inhibition plus the presence of vasodilator therapy.
Neprilysin is a membrane-bound and circulating protease that has been involved in the catabolism of numerous vasoactive peptides, including A-type NP (ANP), bradykinins, angiotensin I, substance P, and endothelin-1 (20, 21) . In many animals, neprilysin is also responsible for the degradation of the BNP (22) .
In particular, mouse BNP is successively cleaved by meprinA and neprilysin (22) . MeprinA cleaves BNP into still-bioactive BNP , which makes mouse BNP amenable to neprilysin cleavage within the ring structure. By contrast, human BNP is poorly sensitive to neprilysin degradation in vitro (23) (24) (25) possibly as it is not cleaved by meprinA (26) . However, a shorter version of human BNP, that is, BNP , is also poorly sensitive to degradation by neprilysin in vitro (27) , suggesting that human BNP is susceptible to neither meprinA nor neprilysin degradation. Instead, human BNP appears to be degraded by leupeptin-sensitive proteases (28, 29) , possibly from the kallikrein family (28) . Nevertheless, human BNP retains affinity to bind neprilysin (23, 27) and has been shown to interfere with ANP cleavage in vitro (27) . Because proBNP is also detected by proBNP assays and differs from BNP by a longer N-terminal extremity, proBNP may also interact with neprilysin. We therefore hypothesized that human irBNP-that is, BNP and proBNP-besides being effectors of the cardiac response to cardiomyocytes stretching in ADHF, could also act as an endogenous neprilysin inhibitor in vivo.
METHODS
This study was approved by local ethic committees and written consent was obtained from patients or next of kin. This study using human samples was performed according to the current revision of the Helsinki Declaration and registered at Clinical Trials.gov under the NCT01374880 identifier.
STUDY POPULATION. The studied population (n ¼ 684) has been previously described (30) . In brief, the cohort consisted of 638 patients presenting to the emergency department with shortness of breath as Biomarkers cutoff values were determined as follows.
First, cutoff of neprilysin activity was determined using a multistep approach: 1) neprilysin activity distribution was centered and standardized using the R scale function; 2) because neprilysin activity distribution was found bimodal, 2 intersecting normal distributions were modeled using a 2-component mixture model (mixtools R package [32] ); and 3) the cutoff was defined as the intersection of the 2 normal distributions. Thus, 2 groups were defined as either "high" or "low" neprilysin activity. .
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Inhibition of Neprilysin Activity by BNP in HF Second, the BNP threshold that best discriminated the 2 aforementioned groups of patients was estimated by receiver-operating characteristic (ROC)
analysis, using the closest top left method using the pROC package (33). Thus, 2 groups were defined as either "high" or "low" BNP plasma concentration.
Third, a similar approach was applied considering substance P as the predictor of high-versus low-BNP groups as defined in the preceding text.
Last, survival of patients with low and high BNP plasma concentrations was compared using Cox regression models. irBNP $916 pg/ml, n ¼ 244). Abbreviations as in Figure 1 .
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Before addition of recombinant BNP, neprilysin activity was similar in both groups (300 pg/ml: proBNP ¼ pro-B-type natriuretic peptide.
When irBNP plasma levels-that is, BNP and proBNP-rose above 916 pg/ml (a value closely tied to prognosis in this population), we observed: 1) a marked reduction in circulating neprilysin activity in vivo; 2) a similar decrease in neprilysin activity in vitro after addition of recombinant BNP or synthetic proBNP to control plasma; and 3) an inverse correlation between circulating neprilysin activity and circulating substance P concentration in vivo.
The similar inhibition of neprilysin by both BNP and proBNP is critical since irBNP consist of a mixture of both peptides (3), and in severe HF patients, proBNP is predominant (4-6). The biological significance of the 916 pg/ml irBNP threshold was further strengthened because the majority of patients could be segregated into 2 groups with respect to circulating neprilysin activity and substance P concentration: irBNP 400 to 916 pg/ml, neprilysin $0.21 nmol/ml/min, substance P <54 pg/ml; and irBNP $916 pg/ml, neprilysin <0.21 nmol/ml/min, substance P $54 pg/ml. Interestingly, these data are reminiscent of those previously published on a limited number of patients with septic shock (35) .
This suggests that irBNP-mediated neprilysin inhibition occurs as soon as irBNP rises above a critical threshold, regardless of the etiology of cardiac stress.
To our knowledge, this is the first demonstration that BNP is an endogenous neprilysin inhibitor in humans. A mechanism for BNP resistance to neprilysin degradation, involving the sequence of the C-terminal tail of the human BNP, has been proposed (27) . Further studies are required to determine the mechanism whereby irBNP inhibits neprilysin.
Neprilysin is involved in the catabolism of numerous vasoactive peptides (21), including bradykinins, ANP, endothelin-1, and substance P. Given the results we obtained with substance P, one may anticipate that the irBNP-mediated neprilysin inhibition also promotes accumulation of other neprilysin substrates (36) . Altogether, the data we presented strongly argue for a model whereby BNP acts as a "molecular switch" that participates in the accumulation of bioactive vasoactive peptides ( Figure 5 ). Heart Association functional class III and IV patients (19) . Taken together, these results strongly suggest that neprilysin inhibition may be the most effective when neprilysin activity is high. Further trials should assess effects of ARNi in patients with plasma irBNP >916 pg/ml for whom neprilysin activity is already low. Vodovar et al.
A U G U S T 2 0 1 5 : 6 2 9 -3 6 STUDY LIMITATIONS. We did not assess the plasma concentrations of other vasoactive peptides that are neprilysin substrates other than substance P, and they should be considered in further studies. Furthermore, the number of patients tested is limited. However, the relationships between plasma irBNP and circulating neprilysin activity, and between neprilysin activity and plasma substance P concentrations were unambiguous. Finally, we did not assess the effect of the truncated forms of BNP on neprilysin activity. However, because neprilysin-mediated BNP cleavage only occurs when the C-terminus is truncated (27) , it is anticipated that most of BNP truncated forms would act as neprilysin inhibitors.
CONCLUSIONS
We showed that elevated irBNP acts as an endogenous France. E-mail: jean-marie.launay@lrb.aphp.fr. 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Immunoreactive BNP is a gold-standard biomarker in HF; a cutoff at 916 pg/ml discriminates patients with high and low neprilysin activity, hence potentially predicts responders to neprilysin inhibition.
TRANSLATIONAL OUTLOOK: We identified 916 pg/ml as a biologically relevant BNP cutoff that discriminated most of the HF patients with different outcomes and vasoactive profiles.
Further analysis is needed to confirm and precisely identify the impact of BNP-mediated neprilysin inhibition, and to determine whether patients across this cutoff need different management. Vodovar et al.
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